Methods and medicaments for administration of ibuprofen

Details Methods and medicaments for administration of ibuprofen Methods and medicaments for administration of ibuprofen

2007-07-17

2011-11-29

Kim, Jennifer M (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S570000, C424S464000

Reexamination Certificate

active

08067451

ABSTRACT:
A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.

REFERENCES:
patent: 4283408 (1981-08-01), Hirata et al.
patent: 4757060 (1988-07-01), Lukacsko et al.
patent: 5037815 (1991-08-01), Lukacsko et al.
patent: 5120850 (1992-06-01), Bod et al.
patent: 5128477 (1992-07-01), Bod et al.
patent: 5204118 (1993-04-01), Goldman
patent: 5364616 (1994-11-01), Singer et al.
patent: 5384130 (1995-01-01), Kamada et al.
patent: 5417980 (1995-05-01), Goldman et al.
patent: 5466436 (1995-11-01), Stables
patent: 5496836 (1996-03-01), De Rocco et al.
patent: 5505983 (1996-04-01), Kamada
patent: 5601843 (1997-02-01), Gimet et al.
patent: 5696165 (1997-12-01), Armitage et al.
patent: 5747068 (1998-05-01), Mendizabal
patent: 5854267 (1998-12-01), Berlin et al.
patent: 5976578 (1999-11-01), Beyerle
patent: 6149943 (2000-11-01), McTeigue et al.
patent: 6294192 (2001-09-01), Patel et al.
patent: 6455518 (2002-09-01), Zenke et al.
patent: 6544556 (2003-04-01), Chen et al.
patent: 6552047 (2003-04-01), Garvey et al.
patent: 6569463 (2003-05-01), Patel et al.
patent: 6613354 (2003-09-01), Depui et al.
patent: 6660303 (2003-12-01), Staniforth
patent: 6923988 (2005-08-01), Patel et al.
patent: 6926907 (2005-08-01), Plachetka
patent: 6951657 (2005-10-01), Zuccarelli et al.
patent: 2003/0069255 (2003-04-01), Plachetka
patent: 2003/0178031 (2003-09-01), Du Pen et al.
patent: 2004/0235802 (2004-11-01), Gimona et al.
patent: 2005/0020671 (2005-01-01), Ibanez et al.
patent: 2005/0053655 (2005-03-01), Yang et al.
patent: 2005/0163847 (2005-07-01), Cheng et al.
patent: 2005/0196459 (2005-09-01), Castan et al.
patent: 2005/0249806 (2005-11-01), Proehl et al.
patent: 2005/0249811 (2005-11-01), Plachetka
patent: 2006/0127478 (2006-06-01), Zerbe et al.
patent: 2006/0177504 (2006-08-01), Sundharadas
patent: 2007/0003490 (2007-01-01), Nijhawan
patent: 2007/0043096 (2007-02-01), Tidmarsh et al.
patent: 2007/0043097 (2007-02-01), Tidmarsh et al.
patent: 2008/0020040 (2008-01-01), Tidmarsh et al.
patent: 2008/0021078 (2008-01-01), Tidmarsh et al.
patent: 2008/0063706 (2008-03-01), Tidmarsh et al.
patent: 2010/0297224 (2010-11-01), Tidmarsh et al.
patent: 0 321 613 (1989-06-01), None
patent: 0320550 (1989-06-01), None
patent: 2 105 193 (1982-09-01), None
patent: 2 105 193 (1983-03-01), None
patent: WO-91/16886 (1991-11-01), None
patent: WO 94/07541 (1994-04-01), None
patent: WO 02/22108 (2002-03-01), None
patent: WO 02/066002 (2002-08-01), None
patent: WO-02/098352 (2002-12-01), None
patent: WO 2004/064815 (2004-08-01), None
patent: WO 2007/012019 (2007-01-01), None
patent: WO-2007/012022 (2007-01-01), None
patent: WO 2008/011426 (2008-01-01), None
patent: WO-2008/027963 (2008-03-01), None
patent: WO-2010/009432 (2010-01-01), None
Brady, W. M., M.D. et al., “Gastroesophageal reflux disease the long and the Short of therapeutic options,”Postgraduate Medicine online, 100(5) (1996).
Chremos, A. N., M.D., “Clinical Pharmacology of Famotidine: A Summary,”J Clin Gastroenterol, 9(Suppl. 2): 7-12 (1987).
Chremos, A. N., M.D., “Pharmacodynamics of Famotidine in Humans,”Am J Med, 81(suppl 4B): 24 (1986).
Edge, D.P., “High dose famotidine in ranitidine resistant severe oesophagitis: a pilot study,”New Zealand Medical Journal, 11:150-152 (1990).
Porro, G. B., “Famotidine in the Treatment of Gastric and Duodenal Ulceration: Overview of Clinical Experience,”Karger(Intl J Gastroenterology)Digestion, 32(suppl. 1): 62-69 (1985).
Santana, et al., “Effect of oral famotidine on 24-hour intragastric acidity,”Postgraduate Medical Journal(UK) 62(Suppl 2):39-42 (1986).
Smith, J. L., “Clinical Pharmacology of Famotidine,”Karger(Intl J Gastroenterology)Digestion, 32(suppl. 1):15-23 (1985).
Taha, A. et al., “Famotidine for the Prevention of Gastric and Duodenal Ulcers caused by Nonsteroidal Antiinflammatoty Drugs,”N. Engl. J. Med., 334:1435-1439 (1996).
Vinayek, R. et al., “Famotidine in the Therapy of gastric Hypersecretory States,”The American Journal of Medicine, 81(S4B):49-59 (1986).
Abraham et al., “National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs,” Gastroenterology 129:1171-1178 (2005).
Altman “Review of Ibuprofen for Osteoarthritis,” Am. J. Med. 10:18 (1984).
Aly et al., “Formulation and evaluation of famotidine and ibuprofen chewable tablets,” Jordan Journal of Applied Sciences-Natural Sciences 6(2):1-7 (2004).
American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs “Recommendations for Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs,” Arthritis & Rheumatism 59(3):1058-1073 (2008).
American Hospital Formulary Service. Drug Information 88, p. 1659-1664 (1988).
American Society of Health-System Pharmacists, AHFS Drug Information 2006. McEvoy, ed., pp. 2902-2908 (2006).
Bell et al., “Time to maximum effect of lansoprazole on gastric pH in normal male volunteers,” Aliment. Pharmacal. Ther. 10(6):897-904 (1996).
Chambers et al., “A Cohort Study of NSAID Use and the Management of Related Gastrointestinal Symptoms by Primary Care Patients” P&T 27(7):462-467 (Jul. 2003).
Copending U.S. Appl. No. 11/489,269, filed Jul. 18, 2006.
Copending U.S. Appl. No. 11/489,275, filed Jul. 18, 2006.
Copending U.S. Appl. No. 11/489,705, filed Jul. 18, 2006.
Davies “Clinical pharmacokinetics of ibuprofen. The first 30 years” Clin. Pharmacokinet. 34:101-154 (1998).
Davies, et al, Ibuprofen: a review of its pharmacological properties, Drugs, (1971), 2:416-446.
De Klerk et al., Abstract of “Patient compliance in rheumatoid arthritis polymyalgia rheumatic, and gout” J. Rheumatol. 30(1):44-54 (Jan. 2003).
Dial et al., “Proton pump inhibitor use and risk of community-acquired Clostridium difficile—associated disease defined by prescription for oral vancomycin therapy,” CMAJ 175(7):745-748 (Sep. 26, 2006).
Doherty et al., “Multiple Endocrine Neoplasias” Cancer: Principles and Practice of Oncology, 6th edition. J.B. Lippincott Co. pp. 1834-1839 (2001).
Drug Facts and Comparisions, 1997 Edition pp. 1387-1399, pp. 1933-1947.
Echizen et al., “Clinical Pharmacokinetics of Famotidine,” Clin. Pharmacokinet. 21(3):178-194 (1991).
European Supplementary Search Report and Search Opinion issued in Patent Application 06800140.3; Mail Date: Nov. 13, 2009, Completion Date: Nov. 2, 2009.
European Supplementary Search Report and Search Opinion issued in Patent Application 07813027.5; Mail Date: Oct. 27, 2009, Completion Date: Oct. 15, 2009.
FDA Facsimile dated May 16, 2006 regarding IND 72,116 HZT-501 (Ibuprofen and Famotidine) EOP2 Meeting.
Gabriel et al., “Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis,” Ann. Intern. Med. 115(10):787-796 (1991).
Geis et al., “Prevalence of Mucosal Lesions in the Stomach and Duodenum Due to Chronic Use of NSAID in Patients with Rheumatoid Arthritis or Osteoarthritis, and Interim Report on Prevention by Misoprostol of Diclofenac Associated Lesions,” J. Rheumatol. 18(suppl 28):11-14 (1991).
Gillin et al., “Problems related to acid rebound and tachyphylaxis” Best Practice & Research Clinical Gastroenterology 15(3):487-495 (2001).
Ho et al., “Risk of Adverse Outcomes Associated with concomitant use of clopidogrel and proton pump inhibitors follong acute coronary syndrome” JAMA 301(9):937-944 (Mar. 4, 2009).
Horizon Therapeutics “Horizon Therapeutics” PowerPoint Presentation, May 12, 2009.
Horizon Therapeutics: “PIND 72,116 / ibuprofen/famotidine combo pr

Affiliated with

Also associated with

Rating

Methods and medicaments for administration of ibuprofen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and medicaments for administration of ibuprofen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and medicaments for administration of ibuprofen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4309396